Success Metrics

Clinical Success Rate
87.5%

Based on 7 completed trials

Completion Rate
88%(7/8)
Active Trials
2(15%)
Results Posted
43%(3 trials)
Terminated
1(8%)

Phase Distribution

Ph not_applicable
5
38%
Ph phase_2
2
15%
Ph phase_1
2
15%
Ph phase_3
3
23%

Phase Distribution

2

Early Stage

2

Mid Stage

3

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
2(16.7%)
Phase 2Efficacy & side effects
2(16.7%)
Phase 3Large-scale testing
3(25.0%)
N/ANon-phased studies
5(41.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

87.5%

7 of 8 finished

Non-Completion Rate

12.5%

1 ended early

Currently Active

2

trials recruiting

Total Trials

13

all time

Status Distribution
Active(2)
Completed(7)
Terminated(1)
Other(3)

Detailed Status

Completed7
unknown3
Active, not recruiting1
Recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
2
Success Rate
87.5%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (16.7%)
Phase 22 (16.7%)
Phase 33 (25.0%)
N/A5 (41.7%)

Trials by Status

active_not_recruiting18%
recruiting18%
unknown323%
completed754%
terminated18%

Recent Activity

2 active trials
Showing 5 of 13
completedphase_1

Therapeutic Plasma Exchange in Adult Patients With Severe Sepsis

NCT04057872
recruitingphase_2

Therapeutic Plasma Exchange in Septic Shock: A Pilot Study

NCT05093075
terminatednot_applicable

RescuE pLAsma eXchange in Severe COVID-19

NCT04685655
completednot_applicable

Therapeutic Plasma Exchange Followed by Convalescent Plasma Transfusion in Severe and Critically Ill COVID-19 Patients

NCT04973488
active_not_recruitingphase_3

The Effects Of Therapeutic Plasma Exchange (TPE) On Age Related Biomarkers And Epigenetics

NCT06534450
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT04057872Phase 1

Therapeutic Plasma Exchange in Adult Patients With Severe Sepsis

Completed
NCT05093075Phase 2

Therapeutic Plasma Exchange in Septic Shock: A Pilot Study

Recruiting
NCT04685655Not Applicable

RescuE pLAsma eXchange in Severe COVID-19

Terminated
NCT04973488Not Applicable

Therapeutic Plasma Exchange Followed by Convalescent Plasma Transfusion in Severe and Critically Ill COVID-19 Patients

Completed
NCT06534450Phase 3

The Effects Of Therapeutic Plasma Exchange (TPE) On Age Related Biomarkers And Epigenetics

Active Not Recruiting
NCT05182515Phase 3

Plasma Exchange in Covid-19 Patients With Anti-interferon Autoantibodies

Unknown
NCT04374149Phase 2

Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS

Completed
NCT04592705Phase 1

Measurement of IL-6 and Secondary Inflammatory Markers Before and After Therapeutic Plasma Exchange (TPE) in Hospitalized Patients

Unknown
NCT04485169Not Applicable

Therapeutic Plasma Exchange for Coronavirus Disease-2019 Triggered Cytokine Release Storm;

Completed
NCT04492501Not Applicable

Investigational Treatments for COVID-19 in Tertiary Care Hospital of Pakistan

Completed
NCT04485975

Therapeutic Plasma Exchange in Thyrotoxicosis

Completed
NCT03844542Not Applicable

Therapeutic Plasma Exchange in the Treatment of Sepsis Associated Multi-Organ Failure [SAMOF-TPE]

Unknown
NCT01210716Phase 3

Evaluation of Therapeutic Plasma Exchange (TPE) Procedure Using the AMICUS Device

Completed

All 13 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
13